PATENT CLAIM ANALYSIS

Application Number: 16074579
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-03
Patent Classification: ["424", "452000"]

Abstract:
The present invention relates to a solid unit oral dosage form comprising sacubitril and valsartan in a 1:1 molar ratio, preferably in the form of the so-called angiotensin receptor neprilysin inhibitor (ARNI) LCZ696, which is a complex salt hydrate of sacubitril, valsartan, and sodium ions, appropriate for use in pediatrics or other patients where low and individual dosing is required or who encounter problems with swallowing e.g. as a result of a disease or because of age, to the manufacture of said solid dosage form and to invention embodiments relating to therapy using said dosage form.

Claim (Index 15):
The minitablet according to  claim 1 , wherein the pharmaceutically acceptable excipients comprise (i) microcrystalline cellulose, (ii) hydroxypropylcellulose, (iii) Mg, Ca or Al stearate, (iv) anhydrous colloidal silica (colloidal silicon dioxide) and (v) talc.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 96.0
- Lexical Diversity: 1.53623
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15755733', '15568550', '16046531', '15735717', '16060297']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7031071249091323
- 35 USC 102 Novelty (BERT): 0.522227540345023
- Combined Prediction Score: 0.6850191664527213
- Mean Citation Score: 229.49906
- Max Citation Score: 275.04184
- Similarity Product: 175.22477398601055

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test